Thermo Fisher Scientific has announced a strategic collaboration with Precision Health Research, Singapore (PRECISE) to accelerate the PRECISE-SG100K study—one of the region’s largest and most diverse population-scale biobank efforts in Singapore.

 

The initiative aims to unlock disease biology in real time by combining large-scale proteomics, clinical datasets, and AI-driven analytics—part of a broader shift toward national biobanks becoming core infrastructure for precision medicine.

 

“Proteomics at population scale represents one of the most powerful opportunities to understand disease in real time across the full continuum of health,” said Marc N. Casper, chairman and chief executive officer of Thermo Fisher. 

 

“By combining our deep scientific expertise with industry-leading technologies, we are helping national health leaders translate complex biological data into insights that can fundamentally transform human health.”

 

At the center of the PRECISE-SG100K program is an integrated proteomics strategy from Thermo Fisher, pairing its Olink Proximity Extension Assay (PEA) platform with the high-resolution Orbitrap Astral mass spectrometry system. The workflow is further strengthened through collaboration with Seer, Inc., whose Proteograph suite enables deep, unbiased protein discovery at scale.

 

Together, the platforms are designed to deliver both high-sensitivity targeted protein measurement and broad discovery proteomics—supporting biomarker identification and disease mechanism mapping across a longitudinal cohort of 100,000 participants.

 

The study’s multi-technology design is intended to improve reproducibility, strengthen regulatory-grade evidence generation, and increase the translational value of population health data—positioning proteomics as a foundational layer of next-generation healthcare systems.

 

“National biobank initiatives require technologies that deliver both breadth and precision,” said Karen Nelson, chief scientific officer at Thermo Fisher. 

 

“By integrating our differentiated technologies, we are enabling high-confidence biomarker identification and accelerating the path to translational application. This complementary strategy sets a new standard for multi-proteomics analysis and empowers researchers to see true disease biology with speed and at scale.”

 

Researchers also highlight the value of integrating datasets across global biobanks such as the UK Biobank Pharma Proteomics Project, FinnGen, and Geisinger's MyCode Community Health Initiative—collectively spanning more than one million samples worldwide.

 

“By applying this integrated proteomics approach across our national cohort, we gain a dynamic view of disease biology within Singapore’s uniquely diverse population,” said John Chambers, chief scientific officer at PRECISE and lead principal investigator of the PRECISE-SG100K study. 

 

“This model strengthens our ability to uncover early molecular signals of disease, understand risk across different global communities and generate insights that can inform the future of population health.”